Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Homocysteine--risk factor or risk indicator?].

Wolf Rafflenbeul1

  • 1Abt. Kardiologie/ Angiologie, Medizinische Hochschule Hannover. wolf@rafflenbeul.com

MMW Fortschritte Der Medizin
|November 24, 2005
PubMed
Summary

Despite vitamin B6, B12, and folic acid lowering homocysteine, recent studies show no reduced cardiovascular risk. Therefore, routine homocysteine screening is not currently recommended for patients with arteriosclerotic vascular disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia.

Atherosclerosisยท2006
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Nutritional Science
  • Clinical Biochemistry

Background:

  • Cardiovascular events occur in patients lacking traditional risk factors like hypertension, high lipids, diabetes, or smoking.
  • Arteriosclerotic vascular disease (ASVD) research continues to identify underlying causes.
  • Homocysteine has been investigated as a potential risk factor for ASVD.

Purpose of the Study:

  • To evaluate the clinical utility of homocysteine screening in patients with ASVD.
  • To assess the impact of homocysteine-lowering vitamins on cardiovascular risk.

Main Methods:

  • Review of accumulated data and recent studies on homocysteine levels and cardiovascular events.
  • Analysis of the association between vitamin B6, B12, and folic acid intake and homocysteine levels.
  • Assessment of the effect of homocysteine reduction on cardiovascular risk.

Main Results:

  • Vitamin B6, B12, and folic acid intake correlate with decreased homocysteine levels.
  • Recent studies have not demonstrated a significant reduction in cardiovascular risk despite lower homocysteine.
  • The data regarding homocysteine's role in ASVD remains equivocal.

Conclusions:

  • Current evidence does not support routine screening for homocysteine in patients with ASVD.
  • The link between homocysteine levels and cardiovascular risk reduction requires further investigation.
  • Focus may need to shift to other underlying causes of ASVD in patients without classical risk factors.

Related Experiment Videos